Results 141 to 150 of about 2,368 (193)

Impact of a national nirsevimab programme on critical care transport of babies with bronchiolitis: a retrospective observational study. [PDF]

Arch Dis Child
Moore T, Afridi A, Aminudin NH, Gibbons C, Grant O, Fucikova H, Moore CM.   +6 more
europepmc   +1 more source

Dual Immunization Against RSV With RSVpreF and Nirsevimab.

JAMA Pediatr
Tréluyer L, Bertrand M, Gabet A, Jabagi MJ, Kolla E, Olié V, Zureik M, Rachas A.   +7 more
europepmc   +1 more source

Protecting infants from RSV: cost-effectiveness of nirsevimab in a real-world study from Chile. [PDF]

Lancet Reg Health Am
Priante E, Baraldi E.
europepmc   +1 more source

The Impact of Limited-Eligibility Nirsevimab on Paediatric Respiratory Syncytial Virus (RSV) Infection and Hospitalisations in the Australian Capital Territory: An Observational Cohort Study. [PDF]

J Paediatr Child Health
Irwin N, Ey S, Chen X, Raina D, Richardson D.   +4 more
europepmc   +1 more source

Nirsevimab in Infants: The Cost of Changing the Paradigm

Mathews Journal of Pediatrics
openaire   +1 more source

In response to the article «Reluctance of parents to immunize their children with nirsevimab»

Anales de Pediatría (English Edition)
David, Andina Martínez, Esther, Fernández Mozo, Rocio, Trincado Lamuño, Jose Antonio, Alonso-Cadenas   +3 more
openaire   +2 more sources

Advancements in Respiratory Syncytial Virus (RSV) Prevention and Treatment in Pediatrics. [PDF]

J Pediatr Pharmacol Ther
Fly JH, Stultz JS, Eiland LS.
europepmc   +1 more source

Real-World Effectiveness of Universal Nirsevimab on Bronchiolitis Incidence: A Regional Hub-Spoke Surveillance Analysis in Liguria, Italy. [PDF]

Pediatr Pulmonol
Mariani M, Brisca G, Strati MF, Buratti S, Ferretti M, Gaiero A, Musso V, Gazzolo A, Ginocchio F, Zerbini K, Minghetti D, Corona MF, De Hoffer L, Pirlo D, Piccotti E, Ramenghi LA, Alberti M, Spiazzi R, Castagnola E, Moscatelli A.   +19 more
europepmc   +1 more source